TAR-210

Other

Phase 3Mechanism not established
Phase 3underway

Evidence outlook · registrational

Non-Muscle Invasive Bladder Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2028-04-06. The sponsor reported topline results of a Phase 1 study on 2026-03-13 (Phase 1 Erda-iDRS results in NMIBC); that is not the registrational readout.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Non-Muscle Invasive Bladder Cancer
NCT06919965 · Janssen Research & Development, LLC
2025-09-10 – 2032-03-16 · Non-Muscle Invasive Bladder Neoplasms
What this study did
Other / comorbidity
NCT06319820 · Janssen Research & Development, LLC
2024-04-18 – 2032-12-31 · Non-Muscle Invasive Bladder Neoplasms
What this study did

Competitive landscape

This drug's own stage for Non-Muscle Invasive Bladder Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
TAR-210: this drugPhase 3Intravesical Drug Delivery System (erdafitinib)—not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
SHR-1501Phase 3UndisclosedIL-15not yet gradedNo reviewed efficacy summary in this indication
TARA-002Phase 3Bacterial immunotherapyInnate and adaptive immune activation (inactivated Streptococcus pyogenes)not yet gradedNo reviewed efficacy summary in this indication
PF-08052667Phase 1Antibody–drug conjugateIntegrin beta-6 (ITGB6)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow TAR-210 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
April 2028 (1)
Phase 3Non-Muscle Invasive Bladder CancerRecruiting
Est. primary completion 2028-04-06 · NCT06919965 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Non-Muscle Invasive Bladder NeoplasmsRecruiting
Est. primary completion 2028-06-28 · NCT06319820 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 March 2026Topline resultPhase 1 Erda-iDRS results in NMIBC